Singapore: China Health Resource (CHR) extended its strategic agreement with the prestigious Chengdu University of Traditional Chinese Medicine (TCM). Chengdu University of TCM is one of the oldest and most established TCM educational and research institutions in China.

CHR's subsidiary Yin Fa and the university's initial 'comprehensive strategic cooperation agreement' started in Feb 12, 2006, and its scientific assistance resulted in the establishment of the GAP standard for Dahurian Angelica Root (DAR). This cooperation agreement extended in 2010 for research efforts for the pharmaceutical usage and enhancement of DAR, which in 2011 extended the agreement for Gastroria.

"This cooperation with the prestigious Chengdu University of TCM in addition to our internal R&D provides us with this ability to provide pharmaceutical grade herbs and proprietary products from our certified GAP ingredients. This also allows us to earn higher profit margins and protect our franchise," said Jiayin Wang , chairman and CEO, China Health Resource.

"CHRI is leveraging its success in creating the fist and only pharmaceutical grade GAP standard Dahurian Angelica Root (DAR) product in the market, extending it to Gastroria, which is a higher profit margin product, and we are now in a position to develop a medical products using herbal medicines that can compete in the international market place while continuing to protect our DAR franchise in China," added Jiayin Wang.

Gastroria is one of the more expensive TCM products in today's market and is used to treat headaches, dizziness, numbness, convulsions in children, and epilepsy. "In addition, the certification awarded by the government as a sanctioned quality enterprise and our partnership with the leading and longest standing TCM research institution gives us a unique strategic position to discover valuable healthcare products for the community," said Jiayin Wang.